CN116712423A - 治疗特定患者群体的神经变性病症的方法 - Google Patents

治疗特定患者群体的神经变性病症的方法 Download PDF

Info

Publication number
CN116712423A
CN116712423A CN202310582394.5A CN202310582394A CN116712423A CN 116712423 A CN116712423 A CN 116712423A CN 202310582394 A CN202310582394 A CN 202310582394A CN 116712423 A CN116712423 A CN 116712423A
Authority
CN
China
Prior art keywords
subject
apoe4
disease
mild
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310582394.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·阿布沙克拉
A·鲍尔
M·托拉尔
J·海伊
J·于
P·科西斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzheon Inc
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116712423(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of CN116712423A publication Critical patent/CN116712423A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202310582394.5A 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法 Pending CN116712423A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22
CN201680052760.4A CN108289870A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680052760.4A Division CN108289870A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法

Publications (1)

Publication Number Publication Date
CN116712423A true CN116712423A (zh) 2023-09-08

Family

ID=58240195

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310582365.9A Pending CN116712422A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法
CN201680052760.4A Pending CN108289870A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法
CN202310582394.5A Pending CN116712423A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202310582365.9A Pending CN116712422A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法
CN201680052760.4A Pending CN108289870A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP3347002B1 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102547164B1 (enExample)
CN (3) CN116712422A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (1) RS64481B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (1) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
KR102547164B1 (ko) * 2015-09-10 2023-06-22 알제온, 인크. 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
CN112867485A (zh) * 2018-08-01 2021-05-28 阿尔泽恩股份有限公司 用于治疗神经变性病症的方法
JP7466520B2 (ja) * 2018-08-01 2024-04-12 アルツェオン・インコーポレーテッド 神経変性障害を治療するためのスルホプロパン酸誘導体
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
WO2020257159A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
KR20240116529A (ko) * 2021-12-09 2024-07-29 알제온, 인크. 알츠하이머병 치료에 사용하기 위한 alz-801
EP4475831A1 (en) * 2022-02-07 2024-12-18 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600730A (zh) * 2006-10-12 2009-12-09 贝鲁斯健康(国际)有限公司 递送3-氨基-1-丙磺酸的方法、化合物、组合物和载体
CN102834095A (zh) * 2009-11-03 2012-12-19 法奈科斯公司 治疗阿尔茨海默病的新疗法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE625212T1 (de) 1992-10-13 2000-11-02 Duke University, Durham Verfahren zum entdecken von krankheit von alzheimer.
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2007502418A (ja) 2003-08-11 2007-02-08 カリフォルニア・インスティテュート・オブ・テクノロジー 微量流体大規模集積
US20060257480A1 (en) * 2005-04-12 2006-11-16 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
MX2009005279A (es) 2006-11-24 2009-05-28 Ac Immune Sa Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
WO2012024616A1 (en) * 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating miild cognitive impairment (mci) and related discorders
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
PT2994160T (pt) * 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
EP3718563A1 (en) * 2014-02-08 2020-10-07 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
KR102547164B1 (ko) * 2015-09-10 2023-06-22 알제온, 인크. 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600730A (zh) * 2006-10-12 2009-12-09 贝鲁斯健康(国际)有限公司 递送3-氨基-1-丙磺酸的方法、化合物、组合物和载体
CN102834095A (zh) * 2009-11-03 2012-12-19 法奈科斯公司 治疗阿尔茨海默病的新疗法

Also Published As

Publication number Publication date
KR20220042480A (ko) 2022-04-05
FI3347002T3 (fi) 2023-08-10
US20220096406A1 (en) 2022-03-31
AU2016319107B2 (en) 2021-02-25
KR102547164B1 (ko) 2023-06-22
US11191742B2 (en) 2021-12-07
AU2016319107A1 (en) 2018-03-22
CN108289870A (zh) 2018-07-17
EP3347002A4 (en) 2019-04-24
KR20180051561A (ko) 2018-05-16
KR102412997B1 (ko) 2022-06-23
JP7128536B2 (ja) 2022-08-31
JP6789579B2 (ja) 2020-11-25
CA2997376C (en) 2024-05-14
WO2017044840A1 (en) 2017-03-16
JP2018526407A (ja) 2018-09-13
SMT202300250T1 (it) 2023-09-06
SI3347002T1 (sl) 2023-12-29
EP3347002B1 (en) 2023-06-07
PL3347002T3 (pl) 2023-11-13
LT3347002T (lt) 2023-09-11
EP3347002A1 (en) 2018-07-18
CN116712422A (zh) 2023-09-08
RS64481B1 (sr) 2023-09-29
HUE062511T2 (hu) 2023-11-28
CA2997376A1 (en) 2017-03-16
US20230414541A1 (en) 2023-12-28
JP2022145949A (ja) 2022-10-04
HK1257874A1 (en) 2019-11-01
EP4275750A3 (en) 2024-01-17
MD3347002T2 (ro) 2023-10-31
DK3347002T3 (da) 2023-08-14
HRP20230809T1 (hr) 2023-10-27
ES2952727T3 (es) 2023-11-03
MX2022003128A (es) 2022-08-02
MX2018003023A (es) 2018-06-06
MX392677B (es) 2025-03-24
JP2020200352A (ja) 2020-12-17
EP4275750A2 (en) 2023-11-15
PT3347002T (pt) 2023-07-27
JP2025065545A (ja) 2025-04-17

Similar Documents

Publication Publication Date Title
JP7128536B2 (ja) 特定の患者集団において神経変性障害を処置する方法
KR101918669B1 (ko) 신경 장애 치료용 신규 조성물
US11116773B2 (en) Method of treating dementia
JP7365426B2 (ja) 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法
US12138269B2 (en) Method of treating dementia
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
US20130059888A1 (en) Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia
KR20120050473A (ko) 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts

Applicant after: ALZHEON, Inc.

Address before: Massachusetts

Applicant before: ALZHEON, Inc.